Related Experiment Videos
Adipose tissue and atherothrombosis.
Marie-Christine Alessi1, H Roger Lijnen, Delphine Bastelica
1Laboratoire d'ématologie, INSERM UMR626, UFR de Médecine, Université de la Méditerranée, Marseille, France. Marie-Christine.Alessi@medecine.univ-mrs.fr
Pathophysiology of Haemostasis and Thrombosis
|February 5, 2005
Summary
Obesity increases cardiovascular risks via insulin resistance. Plasminogen activator inhibitor-1 (PAI-1) in adipose tissue may be a therapeutic target for managing weight gain and associated cardiovascular issues in obese individuals.
Area of Science:
- Endocrinology
- Cardiovascular Science
- Metabolic Research
Background:
- Obesity is linked to higher cardiovascular mortality and morbidity, primarily through insulin resistance.
- Adipose tissue dysfunction in obesity contributes to a pro-inflammatory state, impacting hemostatic and fibrinolytic systems.
- Elevated plasminogen activator inhibitor-1 (PAI-1) levels correlate strongly with insulin resistance and thrombotic risk in obesity.
Purpose of the Study:
- To investigate the role of PAI-1 in obesity-related cardiovascular complications.
- To explore PAI-1 as a potential therapeutic target for managing obesity and its sequelae.
Main Methods:
- Analysis of associations between plasma PAI-1 levels, insulin resistance, and thrombotic tendencies.
- In vivo studies using mouse models to assess PAI-1's effect on adipose tissue growth.
- In vitro experiments examining PAI-1's influence on adipocyte differentiation.
Main Results:
- PAI-1 levels showed the strongest association with the degree of insulin resistance.
- PAI-1 was found to modulate weight gain in mouse models.
- PAI-1 influenced adipocyte differentiation in vitro.
Conclusions:
- PAI-1 plays a significant role in the mechanisms underlying obesity-related cardiovascular morbidity.
- PAI-1 is a potential therapeutic target for controlling weight gain and reducing cardiovascular risk in obese subjects.